Cost Management Insights: SG&A Expenses for Pfizer Inc. and Iovance Biotherapeutics, Inc.

Navigating SG&A Expenses: Pfizer Inc. vs. Iovance Biotherapeutics, Inc.

In the ever-evolving pharmaceutical landscape, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining competitive advantage. Over the past decade, Pfizer Inc. and Iovance Biotherapeutics, Inc. have demonstrated contrasting approaches to cost management. From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually, with a slight dip in 2020. This stability reflects Pfizer's robust operational efficiency and strategic cost control.

Conversely, Iovance Biotherapeutics has seen a dramatic increase in SG&A expenses, growing by over 1,000% from 2014 to 2023. This surge underscores Iovance's aggressive expansion and investment in administrative capabilities to support its growth trajectory. As the industry continues to evolve, these insights into SG&A management offer valuable lessons for companies striving to balance growth with operational efficiency.